{
  "CitationSubset": [
    "IM"
  ],
  "KeywordList": [],
  "GeneralNote": [],
  "OtherAbstract": [],
  "SpaceFlightMission": [],
  "OtherID": [],
  "InvestigatorList": [],
  "PMID": "17304171",
  "DateCompleted": {
    "Year": "2007",
    "Month": "06",
    "Day": "29"
  },
  "DateRevised": {
    "Year": "2019",
    "Month": "11",
    "Day": "10"
  },
  "Article": {
    "ArticleDate": [],
    "Language": [
      "fre"
    ],
    "ELocationID": [],
    "Journal": {
      "ISSN": "0035-3787",
      "JournalIssue": {
        "Volume": "163",
        "Issue": "1",
        "PubDate": {
          "Year": "2007",
          "Month": "Jan"
        }
      },
      "Title": "Revue neurologique",
      "ISOAbbreviation": "Rev Neurol (Paris)"
    },
    "ArticleTitle": "[CARIMS (Cancer Risk In Multiple Sclerosis) project: impact of long-term treatment].",
    "Pagination": {
      "StartPage": "38",
      "EndPage": "46",
      "MedlinePgn": "38-46"
    },
    "Abstract": {
      "AbstractText": [
        "Controversial results have been published on potential link between cancer and multiple sclerosis. Multiple sclerosis has been linked to reduced rates of cancer prior to the era of immunomodulating or immunosuppressive treatments and until today, only 9 studies can be found in the literature. New strategies and early use of IM or IS drugs in MS justify to study and follow patients to detect a potential increase of cancer's incidence in treated patients. It is important to follow and collect prospectively in MS centers, patients with history of cancer, to document histologies, and potential relations with repeated IM or IS treatments. A prospective study is in progress in French MS centers on behalf the Club Francophone de la SEP (CARIMS Project)."
      ]
    },
    "AuthorList": [
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Service de Neurologie, CHU Pasteur, Nice. lebrun.c@chu-nice.fr"
          }
        ],
        "LastName": "Lebrun",
        "ForeName": "C",
        "Initials": "C"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Debouverie",
        "ForeName": "M",
        "Initials": "M"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Vermersch",
        "ForeName": "P",
        "Initials": "P"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Clavelou",
        "ForeName": "P",
        "Initials": "P"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Rumbach",
        "ForeName": "L",
        "Initials": "L"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "de Seze",
        "ForeName": "J",
        "Initials": "J"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Defer",
        "ForeName": "G",
        "Initials": "G"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Berthier",
        "ForeName": "F",
        "Initials": "F"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "CollectiveName": "Club Francophone de la Scl\u00e9rose en Plaques"
      }
    ],
    "PublicationTypeList": [
      "English Abstract",
      "Journal Article",
      "Review"
    ],
    "VernacularTitle": "Cancer et scl\u00e9rose en plaques. Impact des traitements de fonds et pr\u00e9sentation du projet CARIMS (Cancer Risk In Multiple Sclerosis)."
  },
  "MedlineJournalInfo": {
    "Country": "France",
    "MedlineTA": "Rev Neurol (Paris)",
    "NlmUniqueID": "2984779R",
    "ISSNLinking": "0035-3787"
  },
  "ChemicalList": [
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Immunologic Factors"
    },
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Immunosuppressive Agents"
    },
    {
      "RegistryNumber": "8N3DW7272P",
      "NameOfSubstance": "Cyclophosphamide"
    },
    {
      "RegistryNumber": "YL5FZ2Y5U1",
      "NameOfSubstance": "Methotrexate"
    }
  ],
  "MeshHeadingList": [
    {
      "QualifierName": [
        "adverse effects"
      ],
      "DescriptorName": "Cyclophosphamide"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Humans"
    },
    {
      "QualifierName": [
        "adverse effects"
      ],
      "DescriptorName": "Immunologic Factors"
    },
    {
      "QualifierName": [
        "adverse effects"
      ],
      "DescriptorName": "Immunosuppressive Agents"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Incidence"
    },
    {
      "QualifierName": [
        "adverse effects"
      ],
      "DescriptorName": "Methotrexate"
    },
    {
      "QualifierName": [
        "drug therapy"
      ],
      "DescriptorName": "Multiple Sclerosis"
    },
    {
      "QualifierName": [
        "chemically induced",
        "epidemiology"
      ],
      "DescriptorName": "Neoplasms"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Risk Factors"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Time Factors"
    }
  ],
  "NumberOfReferences": "89"
}